Literature DB >> 25495985

Utilizing diversity-oriented synthesis in antimicrobial drug discovery.

Eamon Comer1, Jeremy R Duvall, Maurice duPont Lee.   

Abstract

The development of resistance to existing antimicrobials has created a threat to human health that is not being addressed through our current drug pipeline. Limitations with the use of commercial vendor libraries and natural products have created a need for new types of small molecules to be screened in antimicrobial assays. Diversity oriented synthesis (DOS) is a strategy for the efficient generation of compound collections with a high degree of structural diversity. Diversity-oriented synthesis molecules occupy the middle ground of both complexity and efficiency of synthesis between natural products and commercial libraries. In this review we focus upon the use of diversity-oriented synthesis compound collections for the discovery of new antimicrobial agents.

Entities:  

Keywords:  Trypanosoma cruzi; chemical complexity; diversity-oriented synthesis; drug discovery; hepatitis C virus; infectious disease; malaria; orthopoxviruses

Mesh:

Substances:

Year:  2014        PMID: 25495985     DOI: 10.4155/fmc.14.111

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  3 in total

1.  Novel diversity-oriented synthesis-derived respiratory syncytial virus inhibitors identified via a high throughput replicon-based screen.

Authors:  Jeremy R Duvall; Lynn VerPlank; Barbara Ludeke; Sarah M McLeod; Maurice D Lee; Karthick Vishwanathan; Carol A Mulrooney; Sebastian Le Quement; Qin Yu; Michelle A Palmer; Paul Fleming; Rachel Fearns; Michael A Foley; Christina A Scherer
Journal:  Antiviral Res       Date:  2016-04-06       Impact factor: 5.970

2.  Chemical Space Overlap with Critical Protein-Protein Interface Residues in Commercial and Specialized Small-Molecule Libraries.

Authors:  Yubing Si; David Xu; Khuchtumur Bum-Erdene; Mona K Ghozayel; Baocheng Yang; Paul A Clemons; Samy O Meroueh
Journal:  ChemMedChem       Date:  2018-12-20       Impact factor: 3.466

3.  A High-Throughput Platform to Identify Small-Molecule Inhibitors of CRISPR-Cas9.

Authors:  Basudeb Maji; Soumyashree A Gangopadhyay; Miseon Lee; Mengchao Shi; Peng Wu; Robert Heler; Beverly Mok; Donghyun Lim; Sachini U Siriwardena; Bishwajit Paul; Vlado Dančík; Amedeo Vetere; Michael F Mesleh; Luciano A Marraffini; David R Liu; Paul A Clemons; Bridget K Wagner; Amit Choudhary
Journal:  Cell       Date:  2019-05-02       Impact factor: 41.582

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.